Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
Holding BNTX?
Track your performance easily
BNTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$76.53 - $131.49
Previous Close$113.51
Volume112.51K
Average Volume (3M)832.92K
Market Cap
$27.00B
Enterprise Value$10.17B
Total Cash (Recent Filing)€16.55B
Total Debt (Recent Filing)€219.10M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Mar 10, 2025EPS Estimate
$0.5Last Dividend Ex-Date
Jun 02, 2022Dividend YieldN/A
Share Statistics
EPS (TTM)-2.10
Shares Outstanding237,725,735
10 Day Avg. Volume686,330
30 Day Avg. Volume832,918
Standard Deviation0.23
R-Squared0.00247
Alpha0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)1.33
Price to Sales (P/S)6.32
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$141.03Price Target Upside25.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
BioNTech SE News
PremiumCompany Announcements
FDA Lifts Hold on BioNTech’s Key Cancer Trial
Bulls Say, Bears Say
Bulls Say
Clinical Trials And EfficacyBNTX's PD1/VEGF bispecific BNT327 looks promising in early trials, showing superior efficacy in 6 different cancer settings compared to standard care.
Market PotentialAnalyst sees potential for the PD1/VEGF class to become the largest in immuno-oncology, even surpassing current PD(L)1s.
Pipeline And InnovationBioNTech has a vast pipeline including mRNA cancer vaccines and ADCs, providing additional upside potential beyond the current focus on COVID.
Bears Say
Clinical TrialsBioNTech announced an FDA partial clinical hold on the Ph 3 trial of gotistobart in anti-PD1 relapsed / refractory non-small cell lung cancer.
EarningsBioNTech guided to the low end of its €2.5-3.1B revenue range for FY24 due to pricing pressure and lower demand from middle and low-income countries.
Market CompetitionThere are no obvious indications of monotherapy differentiation for BioNTech’s B7-H3-targeted antibody drug conjugate, BNT324, in comparison to other B7-H3 ADCs and non-B7-H3, topo1i-based ADCs in the clinical landscape.
---
Ownership Overview
― Insiders
3.01% Mutual Funds
12.03% Other Institutional Investors
83.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BNTX FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was $76.53 and its highest was $131.49 in the past 12 months.
What is BioNTech SE’s market cap?
Currently, no data Available
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is Mar 10, 2025 which is in 76 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Nov 04, 2024. The company reported $0.845 earnings per share for the quarter, beating the consensus estimate of -$1.601 by $2.446.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE pays a Notavailable dividend of $1.534 which represents an annual dividend yield of N/A. See more information on BioNTech SE dividends here
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is $0.5.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 237,766,240 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of $0.845 in its last earnings report, beating expectations of -$1.601. Following the earnings report the stock price went down -2.252%.
Which hedge fund is a major shareholder of BioNTech SE?
Among the largest hedge funds holding BioNTech SE’s share is PRIMECAP Management Co. It holds BioNTech SE’s shares valued at 536M.
---
BioNTech SE Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$141.03 (25.24% Upside)
$141.03 (25.24% Upside)
Blogger Sentiment
Bullish
BNTX Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 646.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $160.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 1.6%
Last 30 Days ▲ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.76%
12-Months-Change
Fundamentals
Return on Equity
-2.37%
Trailing 12-Months
Asset Growth
6.33%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
---
BNTX Company Deck
---
BNTX Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, driven by significant revenue growth, advancements in COVID-19 vaccines, and progress within the oncology pipeline. However, there were concerns regarding increased operating costs and contractual disputes. The financial guidance being at the lower end of the range was a noted challenge.Read More>---
BNTX Stock 12 Month Forecast
Average Price Target
$141.03
▲(25.24% Upside)
Technical Analysis
Best Analysts Covering BNTX
1 Year
1 Year Success Rate
7/8 ratings generated profit
1 Year Average Return
+20.90%
reiterated a buy rating 24 days ago
Copying Etzer Darout's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +20.90% per trade.
---